Expression of anaplastic lymphokinase and HER2/neu immunostaining in patients with breast carcinoma

Syed Naqeeb Ali, Aneela Qureshi, Amin Fahim, Muhammad Yousif Khoso


Background: The diagnosis and prognosis of breast cancer is done with various immunomarkers including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2/neu), and Ki-67. The diagnostic utility of Anaplastic Lymphokinase (ALK) and HER2/neu should be explored for better management of breast carcinoma patients. So, the present study was designed to determine the expression of immunostaining with ALK and HER2/neu in patients with breast cancer and to compare the association of ALK expression and HER2/neu with clinicopathological parameters.

Methods: This is a cross sectional multicenter study carried out from October 2016 to March 2017. A total of 140 subjects having breast carcinoma by using non-probability purposive sampling technique were selected. After taking informed consent, tissue samples were taken from received specimen of mastectomy for hematoxylin and eosin stain. The immunohistochemistry for ALK and HER2/neu were assessed on the paraffin blocks of the tumor.

Results: Out of total 140 cases invasive ductal carcinoma (89%), invasive lobular carcinoma (8%), invasive medullary carcinoma (2.1%) and papillary carcinoma (0.7%) were seen. ALK expression was positive in 81 patients (58%) while HER2/neu expression was positive in 53 cases (38%). Significant association was observed between ALK expression with histological grade, lymph node involvement, skin involvement and necrosis. There was also a significant association was seen between HER2/neu expression with lymph node metastasis and necrosis.

Conclusions: Present study shows higher expression of ALK when compared to HER2/neu expression in breast cancer patients.


Anaplastic lymphokinase, Breast cancer, Human epidermal growth factor receptor 2

Full Text:



Siraj AK, Beg S, Jehan Z, Prabhakaran S, Ahmed M, Hussain AR, et al. ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res. 2015 Dec;17(1):127.

Sultana A, Idress R, Naqvi ZA, Azam I, Khan S, Siddiqui AA, et al. Expression of the androgen receptor, pAkt, and pPTEN in breast cancer and their potential in prognostication. Translational Oncol. 2014 Jun 1;7(3):355-62.

Butt Z, Haider SF, Arif S, Khan MR, Ashfaq U, Shahbaz U, Bukhari MH. Breast cancer risk factors: a comparison between pre-menopausal and post-menopausal women. J Pakistan Med Assoc. 2012 Feb 1;62(2):120.

Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;22(6):1-17.

Nickels S, Truong T, Hein R, Stevens K, Buck K, Behrens S, et al. Evidence of gene–environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genetics. 2013 Mar 27;9(3):e1003284.

Faheem M, Mahmood H, Khurram M, Qasim U, Irfan J. Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Cancer Med Sci. 2012;6(283):1-8.

Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancer-reduced CK5 expression in metastases. Basic Clin Res. 2013;1(7):23-34.

Jafarian AH, Salehinejad J, Joushan B, Omidi AA. Immunohistochemical Study of HER2/neu Overexpression in Adenoid Cystic Carcinoma of Salivary Glands. Iranian J Pathol. 2011 Apr 1;6(2):86-92.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Eng J Med. 2012 Nov 8;367(19):1783-91.

Roskoski Jr R. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013 Feb 1;68(1):68-94.

Ishibashi Y, Miyoshi H, Hiraoka K, Arakawa F, Haraguchi T, Nakashima S, et al. Anaplastic lymphoma kinase protein expression, genetic abnormalities, and phosphorylation in soft tissue tumors: Phosphorylation is associated with recurrent metastasis. Oncol Reports. 2015 Apr 1;33(4):1667-74.

Mehrjardi AZ, Vaghefi A. Expression of anaplastic lymphoma kinase protein in human breast cancer. Iran J Pathol. 2013;8(1):27-35.

Wang J, Shen Q, Shi Q, Yu B, Wang X, Cheng K. Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry. J Exp Clin Cancer Res. 2014;33(1):1-7.

Schmidt G, Gerlinger C, Juhasz-Böss I, Stickeler E, Rody A, Liedtke C, et al. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2016 Jun 1;142(6):1369-76.

Tavassoli FA, Devilee P. Pathology and Genetics: tumors of the breast and female genital organs. WHO classification of tumors series. 2004;31(6):133-4.

Shankar A, Roy S, Malik A, Kamal VK, Bhandari R, Kishor K, et al. Contralateral breast cancer: a clinico-pathological study of second primaries in opposite breasts after treatment of breast malignancy. Asian Pac J Cancer Prev. 2015;16(3):1207-11.

Mahmoud MM. Breast cancer in Kirkuk city, Hormone receptors status (estrogen and progesterone) and Her-2/neu and their correlation with other pathologic prognostic variables. Diyala J Med. 2014;6(1):1-4.

Shah RJ, Kothari S, Patel SM. Correlation of Her-2/neu status with estrogen, progesterone receptors and histologic features in breast carcinoma. Ann Pathol Laboratory Med. 2016 Nov 8;3(5):A476-483.

Devi PU, Prasad U, Lakshmi AB, Santa Rao G. A study of correlation of expression of ER, PR and HER2/neu receptor status with clinico-pathological parameters in breast carcinoma at a tertiary care centre. Int J Res Med Sci. 2017 Jan 5;3(1):165-73.

Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev. 2011 Jan 1;12(3):625-9.

Dutta V, Chopra GS, Sahai K, Nema SK. Hormone receptors, Her-2/Neu and chromosomal aberrations in breast cancer. Med J Armed Forces India. 2008;64(1):11-5.

Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev. 2009 Jan 1;10(5):773-8.

Hashmi AA, Edhi MM, Naqvi H, Khurshid A, Faridi N. Molecular subtypes of breast cancer in South Asian population by immunohistochemical profile and Her2neu gene amplification by FISH technique: association with other clinicopathologic parameters. Breast J. 2014 Nov;20(6):578-85.

Ali EM, Ahmed AR, Ali AM. Correlation of breast cancer subtypes based on ER, PR and HER2 expression with axillary lymph node status. Cancer Oncol Res. 2014 May;2(4):51-7.

Shaikh F, Jamal Q, Baig S, Hadi NI, Majeed N. Correlation of Hormone Receptor and HER-2/neu Expression with Clinicopathologic Parameters in Primary Breast Tumors. Asian Pacific J Cancer Prevent. 2016;17(7):3363-7.